Cargando…

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis

(1) Background: FibroTest™ is a multi-marker panel, suggested by guidelines as one of the surrogate markers with acceptable performance for detecting fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). A number of studies evaluating this test have been published after publication of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vali, Yasaman, Lee, Jenny, Boursier, Jérôme, Spijker, René, Verheij, Joanne, Brosnan, M. Julia, Anstee, Quentin M., Bossuyt, Patrick M., Zafarmand, Mohammad Hadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198930/ https://www.ncbi.nlm.nih.gov/pubmed/34072480 http://dx.doi.org/10.3390/jcm10112415

Ejemplares similares

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
por: Lee, Jenny, et al.
Publicado: (2020)

Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
por: Lee, Jenny, et al.
Publicado: (2021)

Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
por: Van Dijk, Anne-Marieke, et al.
Publicado: (2021)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Mak, Anne Linde, et al.
Publicado: (2021)

Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience
por: Yakoob, Rafie, et al.
Publicado: (2015)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
por: Bril, Fernando, et al.
Publicado: (2019)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
por: Newsome, Philip N, et al.
Publicado: (2020)

Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
por: Chindamo, Maria Chiara, et al.
Publicado: (2017)

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
por: Govaere, Olivier, et al.
Publicado: (2023)

Arrhythmogenicity of fibro-fatty infiltrations
por: De Coster, Tim, et al.
Publicado: (2018)

Searching practices and inclusion of unpublished studies in systematic reviews of diagnostic accuracy
por: Korevaar, Daniël A., et al.
Publicado: (2020)

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
por: Vali, Yasaman, et al.
Publicado: (2022)

Fibro-fatty Degeneration in Hypertrophic Cardiomyopathy
por: Chaikriangkrai, Kongkiat, et al.
Publicado: (2018)

Fibro-fatty remodelling in arrhythmogenic cardiomyopathy
por: Kohela, Arwa, et al.
Publicado: (2022)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Case-finding strategies in non-alcoholic fatty liver disease
por: Boursier, Jerome, et al.
Publicado: (2020)

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
por: Johnson, Katherine, et al.
Publicado: (2021)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease
por: Zeybel, Müjdat, et al.
Publicado: (2015)

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
por: Dyson, Jessica K, et al.
Publicado: (2014)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis
por: Hashemi, Seyed-Abbas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8er74nqplos345ev00aqo85oap